In the 6-week studies, 80% of patients were aged 65 years or older1
In the 6-week studies, no differences in safety were reported based on age, gender, or MMSE score
27% had mild cognitive impairment (MMSE 21-24)
The maximum age in the clinical studies was 90 years2
MMSE=Mini-Mental State Examination.
Safety profile demonstrated in placebo-controlled studies1
*Based on 6-week placebo-controlled studies.
In September 2018, FDA issued a statement on the benefit-risk profile of NUPLAZID.4 Read the entire statement at FDA.gov
FDA=Food and Drug Administration.
Important Safety Information for NUPLAZID (pimavanserin)
QT Interval Prolongation: NUPLAZID prolongs the QT interval. The use of NUPLAZID should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong QT interval including Class 1A antiarrhythmics or Class 3 antiarrhythmics, certain antipsychotic medications, and certain antibiotics. NUPLAZID should also be avoided in patients with a history of cardiac arrhythmias, as well as other circumstances that may increase the risk of the occurrence of torsade de pointes and/or sudden death, including symptomatic bradycardia, hypokalemia or hypomagnesemia, and presence of congenital prolongation of the QT interval.